Group 1 - Nan Mining Group signed a procurement contract for iron ore equipment worth 3 billion yuan with Lanyan Weiye Mineral Processing Co., Ltd., for a project processing over 4.6 million tons of ore annually, with an estimated operational cost of 3 billion yuan over 10 years [1] - Guangdong Yuedian A's Dapu Power Plant Phase II Project's Unit 4 has commenced commercial operation, with a total investment of 8.122 billion yuan and an expected annual power generation of 9 billion kilowatt-hours [2] - China Energy Engineering's subsidiary won an EPC general contracting project in Shaanxi Province with a bid amount of approximately 6.864 billion yuan, covering ecological governance, infrastructure, urban renewal, and water conservancy projects, with a total construction period of 36 months [3] Group 2 - ST Dongtong's stock will resume trading on December 30, 2025, entering a delisting arrangement period of 15 trading days, with the last trading date expected to be January 21, 2026 [4] - Roman Co.'s subsidiary signed a contract for a computing power service project worth approximately 156 million yuan with Tianjin Maoyuan Equipment Leasing Co., Ltd. and China Merchants Intelligent Supply Chain Service Co., Ltd. [5] - Hangzhou Thermal Power plans to sign a three-year coal purchase contract with Shanghai Yitai Shenpu for a total of 9 million tons, ensuring stable coal supply from 2026 to 2028 [6] Group 3 - Caitong Securities received approval from the China Securities Regulatory Commission to publicly issue bonds totaling no more than 15 billion yuan [7] - Qipai Technology's application for a stock issuance to specific investors has been approved by the Shanghai Stock Exchange [8] - China Software plans to sell 555 units of X86 servers and two properties to optimize idle assets, with a total estimated value of approximately 6.758 million yuan [10] Group 4 - Xinhua Medical received medical device registration certificates for two products, including an interleukin-6 test kit and a dual test kit for procalcitonin/interleukin-6 [11] - Shandong Haohua announced the resignation of Deputy General Manager Yuan Falin due to personal reasons [12] - Haixiang Pharmaceutical's invested company NWRD06 injection has completed the enrollment of the first subject in its Phase II clinical trial [13] Group 5 - Tiantong Co. terminated the absorption merger of its wholly-owned subsidiary Tiantong Rijing Precision Technology Co., Ltd., retaining its independent legal status [14] - Ruima Precision's subsidiary received a project designation for automotive air suspension systems, with an estimated sales revenue of approximately 1.342 billion yuan over a six-year lifecycle [15] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Qianxing Future to enhance collaboration in the development and manufacturing of quadruped robots [16] Group 6 - Huali Co. terminated the acquisition of a 51% stake in Zhongke Huilian due to failure to reach consensus on key transaction terms [17] - Acolyte's olefin copolymer has passed customer verification and is now in bulk supply for the optical lens sector [18] - Tianjian Technology signed a supplementary agreement for military product price adjustments, expecting a revenue reduction of approximately 256 million yuan [19] Group 7 - Southeast Network Framework won an EPC project bid for the "China Vision Valley Industrial Base" with a total bid amount of 888 million yuan [20] - Baodi Mining plans to acquire 87% of Congling Energy for a total of 685 million yuan through a combination of cash and share issuance [21] - Heng Rui Pharmaceutical received clinical trial approval for multiple drugs, including HRS-6257 tablets for treating acute and chronic pain [22] Group 8 - Zhongxin Saike received a dividend of 60 million yuan from its wholly-owned subsidiary [23] - ST Songfa's subsidiary signed a contract for the construction of an oil tanker with a total contract value of approximately 80 to 100 million USD [24] - China Resources Double Crane received clinical trial approval for hydroxocobalamin injection, aimed at treating metabolic disorders in children [25][26]

人民财讯12月29日电，华润双鹤（600062）12月29日公告，近日，公司收到国家药品监督管理局签发的 羟钴胺注射液《药物临床试验批准通知书》，该药品适用于儿童甲基丙二酸血症伴或不伴同型半胱氨酸 血症患者代谢紊乱的治疗。 ...

（文章来源：第一财经） 华润双鹤公告，公司近日收到国家药品监督管理局签发的羟钴胺注射液《药物临床试验批准通知书》。 羟钴胺注射液适用于儿童甲基丙二酸血症伴或不伴同型半胱氨酸血症患者代谢紊乱的治疗。截至本公告 日，公司针对该药品累计研发投入为人民币1305.81万元(未经审计)。 ...

华润双鹤12月29日公告，近日，公司收到国家药品监督管理局签发的羟钴胺注射液《药物临床试验批准 通知书》。通知书显示，公司于2025年10月22日获得受理通知书，并于2025年12月25日获得《药物临床 试验批准通知书》。截至本公告日，公司针对该药品累计研发投入为人民币1305.81万元(未经审计)。羟 钴胺注射液适用于儿童甲基丙二酸血症伴或不伴同型半胱氨酸血症患者代谢紊乱的治疗。 ...

格隆汇12月29日丨华润双鹤(600062.SH)公布，公司收到国家药品监督管理局签发的羟钴胺注射液(简 称"该药品")《药物临床试验批准通知书》。羟钴胺注射液适用于儿童甲基丙二酸血症伴或不伴同型半 胱氨酸血症患者代谢紊乱的治疗。 ...

华润双鹤公告，近日，公司收到国家药品监督管理局签发的羟钴胺注射液《药物临床试验批准通知 书》。通知书显示，公司于2025年10月22日获得受理通知书，并于2025年12月25日获得《药物临床试验 批准通知书》。截至本公告日，公司针对该药品累计研发投入为人民币1305.81万元（未经审计）。羟 钴胺注射液适用于儿童甲基丙二酸血症伴或不伴同型半胱氨酸血症患者代谢紊乱的治疗。 ...